PD-1与PD-L1抑制剂治疗非黑色素瘤皮肤癌的系统综述
该系统综述纳入51篇文章,分析PD-1/PD-L1抑制剂治疗非黑色素瘤皮肤癌的证据。Merkel细胞癌和皮肤鳞状细胞癌证据最充分(1期和2期临床试验支持);基底细胞癌、皮肤肉瘤、皮脂腺癌和恶性外周神经鞘瘤也显示获益但数据有限;皮肤淋巴瘤似乎无效。
要点
- Merkel细胞癌和皮肤鳞状细胞癌使用PD-1/PD-L1抑制剂证据最充分
- 基底细胞癌、皮肤肉瘤、皮脂腺癌和恶性外周神经鞘瘤显示获益但数据有限
- PD-1/PD-L1抑制剂对皮肤淋巴瘤似乎无效
核心结论
- PD-1和PD-L1抑制剂在多种非黑色素瘤皮肤癌中显示治疗疗效。
研究设计与样本
- 两名评价员独立进行研究筛选、数据提取和批判性评价。
主要发现
- Merkel细胞癌和皮肤鳞状细胞癌的治疗证据最充分,由1期和2期临床试验支持。
- 基底细胞癌、皮肤肉瘤、皮脂腺癌和恶性外周神经鞘瘤使用PD-1/PD-L1抑制剂也显示获益,但数据有限。
- PD-1/PD-L1抑制剂对皮肤淋巴瘤似乎无效。
临床怎么用
- PD-1/PD-L1抑制剂可用于Merkel细胞癌和皮肤鳞状细胞癌的治疗,证据来自1期和2期临床试验。
- 对基底细胞癌、皮肤肉瘤、皮脂腺癌和恶性外周神经鞘瘤可考虑使用PD-1/PD-L1抑制剂,但需注意数据有限。
局限性
- 需要更多研究来确定PD-1和PD-L1抑制剂在非黑色素瘤皮肤癌中的疗效、肿瘤反应性和安全性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy using programmed cell death 1 protein (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors has been increasingly reported in a variety of nonmelanoma skin cancers (NMSCs). OBJECTIVE: To analyze the evidence of PD-1 and PD-L1 inhibitors in the treatment of NMSC. METHODS: A primary literature search was conducted with the PubMed, Cochrane Library, EMBASE, Web of Science, and CINAHL databases through October 28, 2018, to include studies on the use of PD-1 or PD-L1 inhibitors in patients for NMSC. Two reviewers independently performed study selection, data extraction, and critical appraisal. RESULTS: This systematic review included 51 articles. The most robust evidence was in the treatment of Merkel cell carcinoma and cutaneous squamous cell carcinomas, as supported by phase 1 and 2 clinical trials. Treatment of basal cell carcinoma, cutaneous sarcoma, sebaceous carcinoma, and malignant peripheral nerve sheath tumor also showed benefit with PD-1/PD-L1 inhibitors, but data are limited. There does not appear to be efficacy for PD-1/PD-L1 inhibitors in cutaneous lymphomas. LIMITATIONS: More investigation is needed to determine the efficacy, tumor responsiveness, and the safety profile of PD-1 and PD-L1 inhibitors in NMSC. CONCLUSION: PD-1 and PD-L1 inhibitors exhibit treatment efficacy in a variety of NMSCs.
引用
- Choi FD, Kraus CN, Elsensohn AN, et al. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. J Am Acad Dermatol. 2019. PMID: 31163235. doi:10.1016/j.jaad.2019.05.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。